Whether Incruse Ellipta will have a generic version depends on patent and exclusivity protections.
When Could Generic Incruse Ellipta Become Available?
The availability of generic versions of Incruse Ellipta is tied to the expiration of its patents and any associated market exclusivity periods. Information regarding specific patent expiration dates for Incruse Ellipta is available through resources like DrugPatentWatch.com [1]. These dates can be complex, with multiple patents often covering a single drug, and legal challenges can alter the timeline for generic entry.
What is Incruse Ellipta Used For?
Incruse Ellipta is a once-daily, inhaled medication approved for the long-term maintenance treatment of bronchospasm and symptoms associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, in adults [2]. It contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA) [3].
How Does Incruse Ellipta Work?
Umeclidinium works by blocking the action of acetylcholine on muscarinic receptors in the airways. This blockage leads to bronchodilation, meaning it helps to relax and open the airways, making it easier to breathe [3]. Incruse Ellipta is delivered via an Ellipta inhaler device [2].
What Other Medications are Similar to Incruse Ellipta?
Incruse Ellipta belongs to a class of COPD medications known as LAMAs. Other LAMAs include tiotropium (Spiriva), aclidinium (Tudorza Pressair), and glycopyrrolate (Seebri Neohaler) [4]. Often, these medications are used in combination with other types of inhalers, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids, for more comprehensive COPD management [5]. For instance, umeclidinium is also available in combination products with other bronchodilators.
What are the Potential Risks or Side Effects of Incruse Ellipta?
Like all medications, Incruse Ellipta carries potential risks and side effects. Common side effects can include upper respiratory tract infection, sinus inflammation, and chest pain [2]. Less common but serious side effects can involve worsening breathing problems (bronchospasm), eye problems like acute angle-closure glaucoma, and urinary difficulties due to effects on the bladder outflow tract [3]. Patients should discuss any concerns with their healthcare provider.
Who Manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [2].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration (FDA). Incruse Ellipta Prescribing Information.
[3] European Medicines Agency (EMA). Incruse Assessment Report.
[4] National Institutes of Health (NIH). COPD Medications.
[5] Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD COPD Pocket Guide.